

EXPRESS MAIL LABEL NO. EV064092971US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Divisional Of:

Applicants: Antonito Panganiban, et al.
Serial No.: 09/301,978
Filed: April 29, 1999
For: METHOD OF IDENTIFYING MODULATORS OF
HIV-1 VPU AND GAG INTERACTION WITH U
BINDING PROTEIN (Ubp)
Group Art Unit: 1648
Examiner: U. Winkler

INFORMATION DISCLOSURE STATEMENT

Commissioner For Patents
Washington, D.C. 20231

Dear Sir:

Enclosed is a completed form PTO-1449 listing documents that the Applicants in the above-identified application wish to bring to the attention of the Examiner for consideration in connection with the examination on the merits of this application. These documents were cited in parent application 09/301,978.

Respectfully submitted,

Antonito Panganiban, et al.

March 4, 2002

By: Jean C. Baker
Jean C. Baker
Reg. No. 35,433
Quarles & Brady LLP
411 East Wisconsin Avenue
Milwaukee, WI 53202-4497
(414) 277-5709



1046 U.S. PTO
10/090378
03/04/02

[illegible]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	
		Filing Date	March 4, 2002
		First Named Inventor	Antonito Panganiban
		Group Art Unit	
		Examiner Name	
Sheet	2	of	2
		Attorney Docket Number	960296.98849

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		S. Bour, et al., "The Human Immunodeficiency Virus Type 1 Vpu Protein Specifically Binds to the Cytoplasmic Domain of CD4: Implications for a Mechanism of Degradation," J. Virol. 69:1510-1520, 1995	
		M.A. Callahan, et al., "Functional Interaction of Human Immunodeficiency Virus Type 1 Vpu and Gag with a Novel Member of the Tetratricopeptide Repeat Protein Family," J. Virol. 72(6):5189-5197, 1998	
		R.J. Geraghty, et al., "Cell Type-dependence for Vpu Function," J. Med. Primatol. 23:146-150, 1994.	
		Y.-H. Lee, et al., "The HIV-1 Matrix Domain of Gag is Required for Vpu Responsiveness During Particle Release," Virology 237:46-55, 1997.	
		M.S. McBride, et al., "Position Dependence of Functional Hairpins Important for Human Immunodeficiency Virus Type 1 RNA Encapsidation In Vivo," J. Virol. 71(3):2050-2058, 1997	
		M.S. McBride, et al., "Efficient Encapsidation of Human Immunodeficiency Virus Type 1 Vectors and Further Characterization of cis Elements Required for Encapsidation," J. Virol. 71(6):4544-4554, 1997	
		M.D. Schwartz, et al., "Distinct Functions and Requirements for the Cys-His Boxes of the Human Immunodeficiency Virus Type 1 Nucleocapsid Protein during RNA Encapsidation and Replication," J. Virol. 71(12):9295-9305, 1997.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.